<div id="readability-page-1"><ul><li>Russell Rebalance: 3 Stocks Ready to Move Higher</li></ul><p>Insmed, Inc. (NASDAQ:INSM - Free Report) - HC Wainwright cut their FY2028 earnings per share estimates for Insmed in a research note issued to investors on Thursday, December 18th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of $3.15 for the year, down from their prior forecast of $3.42. HC Wainwright has a &#34;Buy&#34; rating and a $230.00 price target on the stock. The consensus estimate for Insmed's current full-year earnings is ($4.56) per share.</p><p>Other equities analysts have also issued reports about the stock. Wolfe Research  set a $167.00 price target on shares of Insmed and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Insmed in a research report on Wednesday, October 8th. Wells Fargo &amp; Company  set a $195.00 target price on Insmed in a research report on Thursday. The Goldman Sachs Group increased their price target on Insmed from $225.00 to $258.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Finally, Cowen  set a $241.00 price target on Insmed in a research note on Thursday. One analyst  has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and an average price target of $205.41.</p><ul><li>Stock Rotation is Underway: Here are the Winners Moving Forward</li></ul><p><b>Check Out Our Latest Research Report on Insmed</b></p><h2>Insmed Stock Down 16.1%</h2><p>Shares of Insmed stock opened at $166.55 on Friday. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The company has a market cap of $35.52 billion, a P/E ratio of -26.91 and a beta of 1.01. The firm's 50 day moving average price is $187.41 and its 200-day moving average price is $142.30. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. </p><p>Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million for the quarter, compared to analysts' expectations of $114.33 million. During the same period in the previous year, the company posted ($1.27) earnings per share. The business's quarterly revenue was up 52.4% compared to the same quarter last year. </p><h2>Insider Transactions at Insmed</h2><p>In related news, insider Michael Alexander Smith sold 27,130 shares of the company's stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the sale, the insider owned 54,902 shares in the company, valued at $10,089,889.56. This represents a 33.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the completion of the transaction, the insider owned 36,461 shares in the company, valued at approximately $7,073,434. This trade represents a 45.14% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 147,130 shares of company stock worth $28,480,051. 3.00% of the stock is owned by insiders. </p><h2>Institutional Trading of Insmed</h2><p>Large investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC lifted its position in  Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 53 shares during the period.  ORG Partners LLC raised its stake in shares of  Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 196 shares during the last quarter.  Hilltop National Bank acquired a new position in shares of  Insmed in the 2nd quarter valued at about $28,000.  Stone House Investment Management LLC acquired a new position in shares of  Insmed in the 3rd quarter valued at about $29,000.  Finally, SBI Securities Co. Ltd. boosted its stake in shares of  Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 166 shares during the last quarter. </p><h2>About Insmed</h2> (Get Free Report)<p>Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Insmed</li><li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li><li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li><li>Insider Trading - What You Need to Know</li><li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li><li>Which Wall Street Analysts are the Most Accurate?</li><li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Insmed Right Now?</h2><p>Before you consider Insmed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p><p>While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

INSM

<p>HC Wainwright has revised its FY2028 earnings per share estimate for Insmed, Inc. from $3.42 to $3.15, maintaining a "Buy" rating with a $230 price target. Other analysts have varied ratings and price targets, with an average rating of "Moderate Buy" and a target of $205.41. Insmed's stock opened at $166.55, with recent insider sales and institutional trading activity noted.</p>

FY2028 Earnings Estimate for Insmed Issued By HC Wainwright